EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms

Le Wang iD, Julie Li, Leah Arbitman, Hailing Zhang, Haipeng Shao, Michael Martin iD, Lynn Moscinski iD, Jinming Song iD

Cancers · 30.05.2025 · 17 (11) · 1834

DOI: 10.3390/cancers17111834 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.05.2025. Verfasst von Le Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Guthrie Clinic Cancer Center, Robert Packer Hospital, Sayre, PA 18840, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers characterized by the excessive production of blood cells in the bone marrow. These disorders arise from acquired genetic driver mutations, with or without underlying genetic predispositions, resulting in the uncontrolled production of red blood cells, white blood cells, or platelets. The excessive cell production and abnormal signaling from driver mutations cause chronic inflammation and a higher risk of blood clots and vascular complications. The primary goals of MPN treatment are to induce remission, improve quality of life and survival, as well as to reduce the risk of complications such as thrombosis, vascular events, and leukemic transformation. This review provides a comprehensive update on the diagnosis and therapeutic advancements in major MPN subtypes, including chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis. It examines these complex diseases from a molecular and evolutionary perspective, highlighting key clinical trials’ long-term follow-up and therapies targeting driver mutations that have transformed treatment strategies. Additionally, several important advancements in addressing challenges such as anemia in myelofibrosis, along with promising emerging therapies, are also discussed.

Schlagwörter

Stichwörter der Autor:innen

Janus kinase 2 (JAK2)chronic myeloid leukemia (CML)cytogenetics response (CyR)essential thrombocythemia (ET)fusion gene between the breakpoint cluster region-Abelson murine leukemia viral…minimal residual disease (MRDmolecular response (MR)myeloproliferative neoplasms (MPNs)polycythemia vera (PV)primary myelofibrosis (PMF)

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Guthrie Clinic Cancer Center, Robert Packer Hospital, Sayre, PA 18840, USA.
  • Department of Hematopathology and Lab Medicines, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
  • University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA.

ORCID-Profile: Le Wang, Michael Martin, Lynn Moscinski, Jinming Song

Zitieren

APA

Wang, L., Li, J., Arbitman, L., Zhang, H., Shao, H., Martin, M., Moscinski, L., & Song, J. (2025). Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms. Cancers, 17(11), 1834. https://doi.org/10.3390/cancers17111834

Vancouver

Wang L, Li J, Arbitman L, Zhang H, Shao H, Martin M, et al. Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms. Cancers. 2025;17(11):1834. doi:10.3390/cancers17111834

BibTeX
@article{Wang2025,
  author = {Wang, Le and Li, Julie and Arbitman, Leah and Zhang, Hailing and Shao, Haipeng and Martin, Michael and Moscinski, Lynn and Song, Jinming},
  title = {Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {11},
  pages = {1834},
  doi = {10.3390/cancers17111834}
}
Kostenlos starten →